Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855097 · ClinicalTrials.gov registry record · NA
Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure
A NA study, sponsored by Daxor Corporation.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT04855097: Completed NA study, sponsored by Daxor Corporation.
NCT04855097 is a NA study that has completed, run by Daxor Corporation. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04855097, a NA study, has completed, sponsored by Daxor Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Diuretic therapy is first-line treatment for acute decompensated heart failure. However, accurate assessment and management of patient blood volume is challenged by the limitations of physical exam and surrogate markers for blood volume. The study primary objective is to determine if goal-directed care as quantified by direct Blood Volume Analysis (Daxor BVA-100™) in addition to usual care results in more appropriate treatment and consistent achievement of euvolemia.
Primary Outcome
Accurately quantify levels and changes to blood volume and red blood cell volume in ADHF inpatients during inpatient stay, and use this data to guide diuretic therapy in the treatment arm.
Interventions
- DIAGNOSTIC_TEST BVA-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
What the finished NCT04855097 record still lists
NCT04855097 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which BVA-100 is the first listed.
NCT04855097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04855097 about?
NCT04855097 is a clinical study titled "Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure". Diuretic therapy is first-line treatment for acute decompensated heart failure. However, accurate assessment and management of patient blood volume is challenged by the limitations of physical exam and surrogate markers for blood volume. The study primary objective is to determine if goal-directed c...
What is the current status of trial NCT04855097?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2022-05-01. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04855097?
The interventions under investigation include: BVA-100 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04855097?
This trial is sponsored by Daxor Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04855097's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI